Monoclonal Antibody Clinical Trials

A listing of Monoclonal Antibody medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 22 clinical trials
Safety Tolerability and Pharmacokinetics Study of Human Monoclonal Antibody BRII-198

This is a phase 1 study in which healthy adult volunteers will receive BRII-198 or placebo and will be assessed for safety, tolerability, and pharmacokinetics.

body mass index
monoclonal antibodies
  • 0 views
  • 19 Feb, 2024
  • 1 location
Safety Tolerability and Pharmacokinetics Study of Human Monoclonal Antibody BRII-196

This is a phase 1 study in which healthy adult volunteers will receive BRII-196 or placebo and will be assessed for safety, tolerability, and pharmacokinetics.

body mass index
monoclonal antibodies
  • 0 views
  • 19 Feb, 2024
  • 1 location
Safety Tolerability and Pharmacokinetics of SCTA01 an Anti-SARS-CoV-2 Monoclonal Antibody in Healthy Chinese Subjects

The purpose of this study is to evaluate the tolerability, safety, pharmacokinetics of SCTA01(anti-SARS-CoV-2 monoclonal antibody) in Healthy Chinese Subjects.

  • 0 views
  • 19 Feb, 2024
  • 1 location
Tolerability Safety Pharmacokinetic Profile and Immunogenicity of a Recombinant Humanized Anti-SARS-CoV-2 Monoclonal Antibody (JS016) for Injection in Chinese Health Subjects

This is a randomized, double-blind, placebo-controlled, phase I clinical study to evaluate the tolerability, safety, pharmacokinetic profile and immunogenicity of JS016 (anti-SARS-CoV-2 monoclonal antibody) injection in Chinese healthy subjects after intravenous infusion of single dose.Eligible patients will be injection JS016 (anti-SARS-CoV-2 monoclonal antibody)

  • 0 views
  • 19 Feb, 2024
  • 1 location
Anti-GITR/Anti-PD1/Stereotactic Radiosurgery in Recurrent Glioblastoma

This is a phase II study of the combination of the GITR agonist monoclonal antibody INCAGN01876, the anti-PD1 monoclonal antibody INCMGA00012, and stereotactic radiosurgery (SRS) for recurrent Glioblastoma (GBM).

bevacizumab
stereotactic radiosurgery
brain surgery
absolute lymphocyte count
radiation necrosis
  • 0 views
  • 19 Feb, 2024
  • 1 location
PTX-35 in Patients With Advanced Solid Tumors

A Phase I, First-in-Human, Dose-Escalation Study to Evaluate the Safety of the Monoclonal Antibody PTX-35 in Patients with Advanced Solid Tumors Refractory to Standard of Care

neutrophil count
antibody therapy
gilbert's syndrome
metastasis
solid tumor
  • 0 views
  • 19 Feb, 2024
  • 1 location
A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors (KEYNOTE-A04)

Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcRIIB), in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors Previously Treated with Anti-PD-1 or Anti-PD-L1 Antibodies

BRAF
solid tumor
cancer
epidermal growth factor receptor
non-small cell lung cancer
  • 0 views
  • 19 Feb, 2024
  • 8 locations
Study of CPI-006 as Immunotherapy for Hospitalized COVID-19 Patients

This Phase 1 single-dose, dose-escalation study is an open label trial evaluating the safety of CPI-006, a humanized monoclonal antibody targeting the CD73 cell-surface ectonucleotidase, as immunotherapy for stable hospitalized mild or moderately symptomatic COVID-19 patients.

nasopharyngeal swab
SARS
cancer
monoclonal antibodies
nasal swab
  • 0 views
  • 19 Feb, 2024
  • 2 locations
A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors

This is an open label Phase 1, First in Human trial of TST001, a recombinant humanized anti-Claudin 18.2 (CLDN18.2) IgG1 monoclonal antibody. It is being tested against advanced and/or metastatic solid tumors including gastric, gastroesophageal junction, pancreatic, colon and lung cancers.

lung cancer
HER2
pancreatic cancer
solid tumor
cancer therapy
  • 0 views
  • 19 Feb, 2024
  • 1 location
CD19 CAR-T Expressing IL7 and CCL19 Combined With PD1 mAb for Relapsed or Refractory Diffuse Large B Cell Lymphoma

At the same time, combined with four generations of CAR-T cells and PD1 monoclonal antibody, PD1 / PDL1 signal pathway was blocked, anti-tumor effect of CAR-T was improved, and immune response and long-term remission rate of DLBCL were improved.

neutrophil count
b-cell lymphoma
large b-cell lymphoma
diffuse large b-cell lymphoma
immunohistochemistry
  • 0 views
  • 19 Feb, 2024
  • 1 location